These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12235528)

  • 1. Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli).
    Hongeng S; Chuansumrit A; Hathirat P; Rerkamnuaychoke B; Chaisiripoomkere W; Jootar S
    Bone Marrow Transplant; 2002 Sep; 30(6):409-10. PubMed ID: 12235528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients.
    Hongeng S; Pakakasama S; Chuansumrit A; Sirachainan N; Sura T; Ungkanont A; Chuncharunee S; Jootar S; Issaragisil S
    Am J Hematol; 2007 Dec; 82(12):1095-8. PubMed ID: 17674372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
    Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete substitution of cyclophosphamide by fludarabine and ATG in a busulfan-based preparative regimen for children and adolescents with beta-thalassemia.
    Sauer M; Bettoni C; Lauten M; Ghosh A; Rehe K; Grigull L; Beilken A; Welte K; Sykora KW
    Bone Marrow Transplant; 2005 Sep; 36(5):383-7. PubMed ID: 15995711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative stem cell transplantation with a haploidentical donor in a class 3 lucarelli severe thalassemia patient.
    Hongeng S; Pakakasama S; Chaisiripoomkere W; Ungkanont A; Jootar S
    Bone Marrow Transplant; 2004 Aug; 34(3):271-2. PubMed ID: 15170161
    [No Abstract]   [Full Text] [Related]  

  • 7. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
    Shapira MY; Or R; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(6):557-61. PubMed ID: 12953126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation for beta-thalassemia major: experience in south of Iran.
    Ramzi M; Nourani H; Zakernia M; Hamidian Jahromi AR
    Transplant Proc; 2004 Oct; 36(8):2509-10. PubMed ID: 15561298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.
    Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Herens C; DePrijck B; Fillet G; Beguin Y
    Bone Marrow Transplant; 2003 Oct; 32(8):829-34. PubMed ID: 14520430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimaerism.
    Ikegame K; Kawakami M; Yamagami T; Maeda H; Onishi K; Taniguchi Y; Fujioka T; Masuda T; Kawase I; Ogawa H
    Clin Lab Haematol; 2005 Apr; 27(2):139-41. PubMed ID: 15784130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second transplant for a thalassemia patient after graft rejection: with immunosuppression and allogeneic peripheral blood stem cell.
    Li CK; Shing MM; Chik KW; Lee V; Tsang KS; Yuen PM
    Pediatr Hematol Oncol; 2002 Jun; 19(4):267-71. PubMed ID: 12051594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
    Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
    Resnick IB; Aker M; Tsirigotis P; Shapira MY; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R
    Bone Marrow Transplant; 2007 Nov; 40(10):957-64. PubMed ID: 17846604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paediatric allogeneic bone marrow transplantation for homozygous beta-thalassaemia, the Dutch experience.
    Ball LM; Lankester AC; Giordano PC; van Weel MH; Harteveld CL; Bredius RG; Smiers FJ; Egeler RM; Vossen JM
    Bone Marrow Transplant; 2003 Jun; 31(12):1081-7. PubMed ID: 12796787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
    Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
    Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation.
    Prinz E; Keil F; Kalhs P; Mitterbauer M; Rabitsch W; Rosenmayr A; Moser K; Schulenburg A; Lechner K; Greinix HT
    Ann Hematol; 2003 May; 82(5):295-8. PubMed ID: 12679886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.